Drug development in Alzheimer’s disease: the path to 2025
The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this t...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 September 2016
|
| In: |
Alzheimer's research & therapy
Year: 2016, Volume: 8, Issue: 1, Pages: 39 |
| ISSN: | 1758-9193 |
| DOI: | 10.1186/s13195-016-0207-9 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s13195-016-0207-9
|
| Author Notes: | Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1670354873 | ||
| 003 | DE-627 | ||
| 005 | 20230427055748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190731s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13195-016-0207-9 |2 doi | |
| 035 | |a (DE-627)1670354873 | ||
| 035 | |a (DE-599)KXP1670354873 | ||
| 035 | |a (OCoLC)1341234980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cummings, Jeffrey L. |d 1948- |e VerfasserIn |0 (DE-588)132176289 |0 (DE-627)519021568 |0 (DE-576)166224294 |4 aut | |
| 245 | 1 | 0 | |a Drug development in Alzheimer’s disease |b the path to 2025 |c Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens |
| 264 | 1 | |c 20 September 2016 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.07.2019 | ||
| 520 | |a The global impact of Alzheimer’s disease (AD) continues to increase, and focused efforts are needed to address this immense public health challenge. National leaders have set a goal to prevent or effectively treat AD by 2025. In this paper, we discuss the path to 2025, and what is feasible in this time frame given the realities and challenges of AD drug development, with a focus on disease-modifying therapies (DMTs). Under the current conditions, only drugs currently in late Phase 1 or later will have a chance of being approved by 2025. If pipeline attrition rates remain high, only a few compounds at best will meet this time frame. There is an opportunity to reduce the time and risk of AD drug development through an improvement in trial design; better trial infrastructure; disease registries of well-characterized participant cohorts to help with more rapid enrollment of appropriate study populations; validated biomarkers to better detect disease, determine risk and monitor disease progression as well as predict disease response; more sensitive clinical assessment tools; and faster regulatory review. To implement change requires efforts to build awareness, educate and foster engagement; increase funding for both basic and clinical research; reduce fragmented environments and systems; increase learning from successes and failures; promote data standardization and increase wider data sharing; understand AD at the basic biology level; and rapidly translate new knowledge into clinical development. Improved mechanistic understanding of disease onset and progression is central to more efficient AD drug development and will lead to improved therapeutic approaches and targets. The opportunity for more than a few new therapies by 2025 is small. Accelerating research and clinical development efforts and bringing DMTs to market sooner would have a significant impact on the future societal burden of AD. As these steps are put in place and plans come to fruition, e.g., approval of a DMT, it can be predicted that momentum will build, the process will be self-sustaining, and the path to 2025, and beyond, becomes clearer. | ||
| 700 | 1 | |a Frölich, Lutz |d 1956- |e VerfasserIn |0 (DE-588)1028327099 |0 (DE-627)730567516 |0 (DE-576)375813160 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's research & therapy |d London : BioMed Central, 2009 |g 8(2016,1) Artikel-Nummer 39, 12 Seiten |h Online-Ressource |w (DE-627)605683557 |w (DE-600)2506521-X |w (DE-576)309210623 |x 1758-9193 |7 nnas |a Drug development in Alzheimer’s disease the path to 2025 |
| 773 | 1 | 8 | |g volume:8 |g year:2016 |g number:1 |g pages:39 |g extent:12 |a Drug development in Alzheimer’s disease the path to 2025 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s13195-016-0207-9 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190731 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1028327099 |a Frölich, Lutz |m 1028327099:Frölich, Lutz |d 60000 |e 60000PF1028327099 |k 0/60000/ |p 4 | ||
| 999 | |a KXP-PPN1670354873 |e 350182128X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1670354873"],"doi":["10.1186/s13195-016-0207-9"]},"note":["Gesehen am 31.07.2019"],"name":{"displayForm":["Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. Jack, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens"]},"recId":"1670354873","language":["eng"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Drug development in Alzheimer’s disease the path to 2025Alzheimer's research & therapy","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["605683557"],"zdb":["2506521-X"],"issn":["1758-9193"]},"note":["Gesehen am 31.07.2017"],"recId":"605683557","origin":[{"dateIssuedKey":"2009","publisherPlace":"London","publisher":"BioMed Central","dateIssuedDisp":"2009-"}],"title":[{"title":"Alzheimer's research & therapy","title_sort":"Alzheimer's research & therapy"}],"pubHistory":["1.2009 -"],"part":{"volume":"8","year":"2016","extent":"12","issue":"1","pages":"39","text":"8(2016,1) Artikel-Nummer 39, 12 Seiten"},"language":["eng"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"20 September 2016"}],"title":[{"title_sort":"Drug development in Alzheimer’s disease","title":"Drug development in Alzheimer’s disease","subtitle":"the path to 2025"}],"person":[{"family":"Cummings","display":"Cummings, Jeffrey L.","role":"aut","roleDisplay":"VerfasserIn","given":"Jeffrey L."},{"family":"Frölich","display":"Frölich, Lutz","role":"aut","roleDisplay":"VerfasserIn","given":"Lutz"}],"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a CUMMINGSJEDRUGDEVELO2020 | ||